Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Yposkesi
Yposkesi
X
LinkedIn
Trending Articles
ICROM has acquired HOLODIAG
ICROM srl, an italian API CDMO, has acquired the French-based Contract Research Organization HOLODIAG sas specialized in solid state studies and crystallization services of...
Blood plasma processing: when every drop counts
Plasma derivatives obtained from human blood support the treatment of various diseases — from haemophilia and antigen defects to COVID-19. The products are in high demand and...
Rentschler Biopharma boosts UK end-to-end lentiviral vector manufacturing capabilities
The company can now develop and produce LVVs for the biopharmaceutical market, which have a high potential in treating a range of diseases
IC Biomedical confirms Biopharma Group as its cryogenic storage vessel service provider
IC Biomedical has designated Biopharma Group as its Premier Service Provider for the full range of cryogenic storage vessels across the UK and Ireland
What’s the difference between a factory acceptance test and site acceptance testing?
When manufacturing complex machinery in industries such as pharmaceuticals or fine chemicals, extensive equipment testing must be carried out before commissioning
Upcoming event
Boston Biotech Week
23-26 September, 2024 | Convention and exhibition | Boston, US
See all
Related Content
Manufacturing
SK pharmteco subsidiary Yposkesi launches AAVelocity, a plug-and-play AAV platform
Designed to shorten turnaround on manufacturing AAVs, this new platform offers CGT developers more flexibility when producing viral vectors for clinical and commercial use
Ingredients
Yposkesi launches lentiviral vector production platform optimised for higher yields
Yposkesi, SK pharmteco’s clinical and commercial viral vector manufacturing arm for cell and gene therapies, has launched LentiSure
Research & Development
Yposkesi joins BioPhorum CGT consortium
Key challenges facing biopharmaceutical manufacturers include ensuring production efficiency while operating in a rapidly evolving regulatory environment
Finance
Yposkesi begins construction of second bioproduction site
Backed by majority shareholder SK Pharmteco, Yposkesi is investing $71m in the 5,000 sqm facility. The construction is projected to create approximately 80 jobs by 2023
Manufacturing
Axovant Gene Therapies chooses Yposkesi for viral vector production
The initial focus of the agreement will be on AAV-based gene therapies
Pharmaceutical
Yposkesi appoints Dr Fraser Wright as Senior Advisor
Subscribe now